Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May-Jun;36(3):1302-1315.
doi: 10.21873/invivo.12831.

Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma

Stamatis J Karakatsanis  1 , Maria Bouzani  2 , Argyris Symeonidis  3 , Maria K Angelopoulou  4 , Sotirios G Papageorgiou  5 , Michail Michail  6 , Gabriella Gainaru  7 , Georgia Kourti  1   2 , Sotirios Sachanas  8 , Christina Kalpadakis  9 , Eirini Katodritou  10 , Theoni Leonidopoulou  11 , Ioannis Kotsianidis  12 , Eleftheria Hatzimichael  13 , Maria Kotsopoulou  14 , Maria Dimou  4 , Eleni Variamis  15 , Dimitrios Boutsis  16 , Nick Kanellias  17 , Maria N Dimopoulou  4 , Evridiki Michali  18 , George Karianakis  7 , Pantelis Tsirkinidis  19 , Chryssa Vadikolia  20 , Christos Poziopoulos  21 , Anna Pigaditou  22 , Effimia Vrakidou  7 , Theophanis Economopoulos  21 , Lydia Kyriazopoulou  13 , Marina P Siakantaris  4 , Marie-Christine Kyrtsonis  23 , Konstantinos Anargyrou  24 , Maria Papaioannou  25 , Evdoxia Hatjiharissi  10   25 , Elissavet Vervessou  26 , Maria Tsirogianni  27 , Maria Palassopoulou  28 , Ekaterini Stefanoudaki  29 , Panayiotis Zikos  30 , Panayiotis Tsirigotis  5 , Gerassimos Tsourouflis  31 , Theodora Assimakopoulou  11 , Evgenia Verrou  10 , Helen Papadaki  9 , Polixeni Lampropoulou  14 , Meletios-Athanasios Dimopoulos  17 , Vassiliki Pappa  5 , Kostas Konstantopoulos  4 , Themis Karmiris  2 , Paraskevi Roussou  1 , Panayiotis Panayiotidis  4 , Gerassimos A Pangalis  4   8 , Theodoros P Vassilakopoulos; Hellenic Cooperative Lymphoma Group
Affiliations

Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma

Stamatis J Karakatsanis et al. In Vivo. 2022 May-Jun.

Abstract

Background/aim: Primary mediastinal large B-cell lymphoma (PMLBCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody rituximab into current therapeutic regimens. Evidence, however, on the optimal time interval between consecutive chemoimmunotherapy (CIT) cycles is still scarce. This study aimed to evaluate the efficacy outcomes of the more commonly administered 3-weekly regimens to the biweekly ones in a PMLBCL patients' population, who were mostly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP-21) or R-CHOP-14.

Patients and methods: We retrospectively studied our cohort of consecutively treated PMLBCL patients, focusing on their treatment density, in order to determine possible differences in treatment outcomes.

Results: CIT, in the form of both R-CHOP-21 as well as R-CHOP-14 (or similar regimens), is highly active in PMLBCL, with low rates of early treatment failure. In our cohort of patients, R-CHOP-14 did not result in a meaningful improvement of freedom from progression (FFP) or overall survival (OS).

Conclusion: Both R-CHOP-14 and R-CHOP-21 are probably equally effective in PMLBCL, yet further, prospective, randomized studies are warranted to clarify whether dose-dense regimens can be associated with better disease control and long-term results.

Keywords: Large B-cell lymphoma; PET; R-CHOP; primary mediastinal; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The Authors declare that they have no conflicts of interest in relation to this study.

Figures

Figure 1
Figure 1. Freedom from progression (FFP) according to chemotherapy regimen (R-CHOP-21 vs. R-CHOP-14).
Figure 2
Figure 2. Overall survival (OS) according to chemotherapy regimen (R-CHOP-21 vs. R-CHOP-14).
See this image and copyright information in PMC

References

    1. Boleti E, Johnson PW. Primary mediastinal B-cell lymphoma. Hematol Oncol. 2007;25(4):157–163. doi: 10.1002/hon.818. - DOI - PubMed
    1. Gaulard P, Harris NL, Pileri SA, Stein H, Kovrigina AM, Jaffe ES, Moller P, Gascoyne RD. Lyon, France, IARC. 2017. Primary mediastinal (thymic) large B-cell lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th Edition). Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (eds) p. pp. 314.
    1. Rieger M, Österborg A, Pettengell R, White D, Gill D, Walewski J, Kuhnt E, Loeffler M, Pfreundschuh M, Ho AD, MabThera International Trial (MInT) Group Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011;22(3):664–670. doi: 10.1093/annonc/mdq418. - DOI - PubMed
    1. Vassilakopoulos TP, Pangalis GA, Katsigiannis A, Papageorgiou SG, Constantinou N, Terpos E, Zorbala A, Vrakidou E, Repoussis P, Poziopoulos C, Galani Z, Dimopoulou MN, Kokoris SI, Sachanas S, Kalpadakis C, Dimitriadou EM, Siakantaris MP, Kyrtsonis MC, Dervenoulas J, Dimopoulos MA, Meletis J, Roussou P, Panayiotidis P, Beris P, Angelopoulou MK. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist. 2012;17(2):239–249. doi: 10.1634/theoncologist.2011-0275. - DOI - PMC - PubMed
    1. Savage KJ. Primary mediastinal Large B-cell Lymphoma. Blood. 2021:blood.2020008376. doi: 10.1182/blood.2020008376. - DOI - PubMed

MeSH terms